Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

Annane, Djillali; Mira, Jean Paul; Ware, Lorraine B; Gordon, Anthony C; Sevransky, Jonathan; Stüber, Frank; Heagerty, Patrick J; Wellman, Hugh F; Neira, Mauricio; Mancini, Alexandra Dj; Russell, James A (2012). Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). Annals of intensive care, 2(1), p. 15. Heidelberg: Springer 10.1186/2110-5820-2-15

Full text not available from this repository. (Request a copy)

A genomic biomarker identifying patients likely to benefit from drotrecogin alfa (activated) (DAA) may be clinically useful as a companion diagnostic. This trial was designed to validate biomarkers (improved response polymorphisms (IRPs)). Each IRP (A and B) contains two single nucleotide polymorphisms that were associated with a differential DAA treatment effect.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy

UniBE Contributor:

Stüber, Frank

ISSN:

2110-5820

Publisher:

Springer

Language:

English

Submitter:

Jeannie Wurz

Date Deposited:

04 Oct 2013 14:33

Last Modified:

23 Jan 2018 12:16

Publisher DOI:

10.1186/2110-5820-2-15

PubMed ID:

22694772

URI:

https://boris.unibe.ch/id/eprint/13016 (FactScience: 219517)

Actions (login required)

Edit item Edit item
Provide Feedback